CD274 and cancer: In the past few years, immunotherapy has revolutionized cancer treatment, especially based on antibodies targeting immune checkpoints, such as the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein (PD-1), or its ligand (PD-L1).1